专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080241839A1 Method for correlating differential brain images and genotypes; genes that correlate with differential brain images 审中-公开
标题翻译：差异脑图像和基因型相关的方法; 与差异脑图像相关的基因
公开(公告)号：US20080241839A1
公开(公告)日：2008-10-02
申请号：US11974516
申请日：2007-10-12
申请人： Steven Potkin , James H. Fallon , Fabio Macciardi , Jessica Turner , David Keator
发明人： Steven Potkin , James H. Fallon , Fabio Macciardi , Jessica Turner , David Keator
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q1/6881 , C12Q2600/156 , C12Q2600/158
摘要： Methods of assigning quantitative phenotype measurement summary statistics to differential brain image information associated with neuropsychiatric disorders are provided. Summary statistics are correlated to genotype information to identify loci that correlate with differential brain image phenotypes. Methods of identifying modulators of genes at the loci are provided, as well as modulators identified by the methods. Systems for correlating polymorphisms and differential brain image phenotypes, for identifying modulators and for making correlations between differential brain activation phenotypes and genotypes are also providedaf.
摘要翻译：提供了将定量表型测量概要统计量分配给与神经精神障碍相关的差异脑图像信息的方法。摘要统计与基因型信息相关，以识别与差异脑图像表型相关的基因座。提供了确定位点基因调节剂的方法，以及通过该方法鉴定的调节剂。还提供了用于识别多态性和差异脑图像表型的系统，用于识别调节剂并使差异脑活化表型和基因型之间的相关性。

2. 发明申请

US20150045306A1 DETERMINATION OF SINGLE NUCLEOTIDE POLYMORPHISMS USEFUL TO PREDICT RESPONSE FOR GLATIRAMER ACETATE 审中-公开
标题翻译：单核苷酸多态性的测定有助于预测乙酰胆碱的反应
公开(公告)号：US20150045306A1
公开(公告)日：2015-02-12
申请号：US14467954
申请日：2014-08-25
申请人： Amir Tchelet , Fabio Macciardi , Joseph Levy
发明人： Amir Tchelet , Fabio Macciardi , Joseph Levy
IPC分类号： C12Q1/68 , A61K45/06 , A61K38/16
CPC分类号： C12Q1/6883 , A61K38/02 , A61K38/16 , A61K45/06 , C12Q2600/106 , C12Q2600/156
摘要： This invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of 1) identifying whether the human subject is a predicted responder to glatiramer acetate by determining the genotype of the subject at one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of the SNPs in Group 1; and 2) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.
摘要翻译：本发明提供了一种治疗患有多发性硬化的人类受试者或与多发性硬化一致的单一临床攻击的方法，所述药物组合物包含乙酸格拉默和药学上可接受的载体，包括以下步骤：1）鉴定人受试者是否为预测通过在选自组1中的SNP的一个或多个单核苷酸多态性（SNP）上确定受试者的基因型来响应乙酸格拉司坦; 以及2）如果将受试者鉴定为乙酸格拉默的预测应答者，则向受试者施用包含乙酸格拉默和药学上可接受的载体的药物组合物。

3. 发明申请

US20070249518A1 Compositions and Methods for Treating Mental Disorders 审中-公开
标题翻译：治疗精神疾病的组成和方法
公开(公告)号：US20070249518A1
公开(公告)日：2007-10-25
申请号：US11575838
申请日：2005-12-09
申请人： Ilya Chumakov , Daniel Cohen , Fabio Macciardi
发明人： Ilya Chumakov , Daniel Cohen , Fabio Macciardi
IPC分类号： A61K38/00 , C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156
摘要： The present invention relates, generally, to methods and compositions for detecting or treating mental disorders, such as schizophrenia or bipolar disorder. The present invention more particularly discloses the identification of human genes that can be used for the diagnosis, prevention and treatment of schizophrenia, bipolar disorder and related disorders, as well as for the screening of therapeutically active drugs to treat said disorders. The invention further discloses specific polymorphisms or alleles of the KCNQ3 gene that are related to schizophrenia or bipolar disorder, as well as diagnostic tools and kits based on these markers. The invention can be used in the diagnosis of or predisposition to, detection, prevention and/or treatment of schizophrenia, bipolar disorder and related disorders.
摘要翻译：本发明一般涉及用于检测或治疗精神障碍如精神分裂症或双相情感障碍的方法和组合物。本发明更具体地公开了可用于诊断，预防和治疗精神分裂症，双相性精神障碍和相关病症以及用于筛选治疗性活性药物以治疗所述疾病的人类基因的鉴定。本发明还公开了与精神分裂症或双相性精神障碍相关的KCNQ3基因的特异性多态性或等位基因，以及基于这些标记的诊断工具和试剂盒。本发明可用于诊断或倾向于检测，预防和/或治疗精神分裂症，双相情感障碍和相关疾病。

4. 发明申请

US20080254451A1 Compositions and Methods for Treating Schizophrenia and Related Disorders 审中-公开
标题翻译：治疗精神分裂症和相关疾病的组合物和方法
公开(公告)号：US20080254451A1
公开(公告)日：2008-10-16
申请号：US11575844
申请日：2005-12-12
申请人： Ilya Chumakov , Daniel Cohen , Fabio Macciardi
发明人： Ilya Chumakov , Daniel Cohen , Fabio Macciardi
IPC分类号： C12Q1/68 , C12Q1/02 , G01N33/566 , G01N33/53
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/172
摘要： The present invention relates, generally, to methods and compositions for detecting or treating mental disorders, such as schizophrenia. The present invention more particularly discloses the identification of human genes which can be used for the diagnosis, prevention and treatment of schizophrenia and related disorders, as well as for the screening of therapeutically active drugs. The invention further discloses specific polymorphisms or alleles of the CNTFR gene that are related to schizophrenia, as well as diagnostic tools and kits based on these markers. The invention can be used in the diagnosis of or predisposition to, detection, prevention and/or treatment of schizophrenia and related disorders.
摘要翻译：本发明一般涉及用于检测或治疗精神障碍如精神分裂症的方法和组合物。本发明更具体地公开了可用于诊断，预防和治疗精神分裂症及相关病症以及用于筛选治疗活性药物的人类基因的鉴定。本发明还公开了与精神分裂症相关的CNTFR基因的特异性多态性或等位基因，以及基于这些标记的诊断工具和试剂盒。本发明可用于诊断或倾向于检测，预防和/或治疗精神分裂症及相关疾病。

5. 发明授权

US09499868B2 Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate 有权
标题翻译：用于预测醋酸格拉默的反应的单核苷酸多态性的测定
公开(公告)号：US09499868B2
公开(公告)日：2016-11-22
申请号：US14467954
申请日：2014-08-25
申请人： Amir Tchelet , Fabio Macciardi , Joseph Levy
发明人： Amir Tchelet , Fabio Macciardi , Joseph Levy
IPC分类号： A61K38/16 , C12Q1/68 , A61K45/06
CPC分类号： C12Q1/6883 , A61K38/02 , A61K38/16 , A61K45/06 , C12Q2600/106 , C12Q2600/156
摘要： This invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of 1) identifying whether the human subject is a predicted responder to glatiramer acetate by determining the genotype of the subject at one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of the SNPs in Group 1; and 2) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.
摘要翻译：本发明提供了一种治疗患有多发性硬化的人类受试者或与多发性硬化一致的单一临床攻击的方法，所述药物组合物包含乙酸格拉默和药学上可接受的载体，包括以下步骤：1）鉴定人受试者是否为预测通过在选自组1中的SNP的一个或多个单核苷酸多态性（SNP）上确定受试者的基因型来响应乙酸格拉司坦; 以及2）如果将受试者鉴定为乙酸格拉默的预测应答者，则向受试者施用包含乙酸格拉默和药学上可接受的载体的药物组合物。

6. 发明授权

US07101666B2 Involvement of the BDNF gene in mood disorders 有权
公开(公告)号：US07101666B2
公开(公告)日：2006-09-05
申请号：US10231297
申请日：2002-08-30
申请人： James Lowery Kennedy , Fabio Macciardi
发明人： James Lowery Kennedy , Fabio Macciardi
IPC分类号： C12Q1/68 , C07H21/04
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： Methods and kits for determining susceptibility of a patient to mood disorders are described. The method involves analyzing a sample comprising nucleic acids from a patient for a polymorphism in the promoter region of the BDNF gene.

7. 发明授权

US09408854B2 Methods and systems for pharmacogenomic treatment of cardiovascular conditions 有权
标题翻译：用于药物基因组治疗心血管疾病的方法和系统
公开(公告)号：US09408854B2
公开(公告)日：2016-08-09
申请号：US13502518
申请日：2010-10-18
申请人： Giuseppe Bianchi , Patrizia Ferrari , Fabio Macciardi
发明人： Giuseppe Bianchi , Patrizia Ferrari , Fabio Macciardi
IPC分类号： C12Q1/68 , A61K31/58 , C07J17/00 , A61K31/56
CPC分类号： A61K31/56 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156
摘要： Methods and systems are provided herein that are based on the effects of genetic variations on the biological activities associated to rostafuroxin in an individual. In particular, compositions, methods and systems are herein described that are based on an indentified influence on an individual response to rostafuroxin of one or more polymorphisms in an intergenic or intragenic region of a gene selected from the group consisting of KCNS3, THSD7A, FAM46A, LOC389970, HLA-G, and TTC29, and/or a genetic variation in linkage disequilibrium therewith.
摘要翻译：本文提供的方法和系统是基于遗传变异对与个体中的罗夫沙罗毒素相关的生物活性的影响。特别地，本文描述了基于对选自KCNS3，THSD7A，FAM46A的基因或基因内区域中的一种或多种多态性的罗夫沙罗的单个应答的影响的组合物，方法和系统， LOC389970，HLA-G和TTC29，和/或与其连锁不平衡的遗传变异。

8. 发明申请

US20090136450A1 THERAPY FOR NEUROLOGICAL DISEASES 审中-公开
标题翻译：治疗神经病
公开(公告)号：US20090136450A1
公开(公告)日：2009-05-28
申请号：US11997185
申请日：2006-07-31
申请人： Ilya Chumakov , Daniel Cohen , Fabio Macciardi
发明人： Ilya Chumakov , Daniel Cohen , Fabio Macciardi
IPC分类号： A61K38/21 , A61K31/506 , A61P25/00 , G01N33/68 , C12Q1/68 , A61K31/404
CPC分类号： A61K45/06 , A61K31/506 , A61K38/21 , C12Q1/6883 , C12Q2600/118 , C12Q2600/156 , G01N33/6896 , G01N2333/70596 , G01N2333/912 , G01N2800/285 , G01N2800/50 , G01N2800/52 , A61K2300/00
摘要： The present invention relates to compositions and methods for treating neurological diseases in a subject. More specifically, the invention relates to combination therapies for treating such diseases, using a c-kit inhibitor and a neuroactive compound. The invention may be used against a variety of demyelinating diseases, including multiple sclerosis, in any mammalian subject, particularly human subjects, and at various stages of disease progression.
摘要翻译：本发明涉及用于治疗受试者的神经系统疾病的组合物和方法。更具体地，本发明涉及使用c-kit抑制剂和神经活性化合物治疗这些疾病的组合疗法。本发明可以针对任何哺乳动物受试者，特别是人类受试者以及疾病进展的各个阶段的各种脱髓鞘疾病，包括多发性硬化。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式